| eccDNA (EGFR) |
Glioblastoma |
Endogenous enhancer elements |
Morton et al., 2019
|
| ecDNA (ecEGFRx1, ecCCAT1, ecEGFR, and ecCCDC26) |
Glioblastoma |
Uneven segregation of ecDNA during mitosis |
Yi et al., 2022
|
| eccDNA (PDGFRA, CDK4) |
Radiation-induced high-grade glioma |
eccDNA-mediated amplification of oncogenes |
DeSisto et al., 2021
|
| eccDNA (TRPS1) |
Breast cancer |
TRPS1-driven genome deletions |
Yang et al., 2021b
|
| ecDNA (ecMYC) |
Prostate cancer |
Mobile transcriptional enhancers |
Zhu et al., 2021
|
| ecDNA/eccDNA (cyclin-E1, ERBB2, CDK12, EGFR, MYC) |
Gastric cardia adenocarcinoma |
Focal amplifications of oncogene prognostic molecular markers |
Zhao et al., 2021
|
| eccDNA (RAB3B) |
Hypopharyngeal squamous cell carcinoma |
Promote cisplatin resistance |
Lin et al., 2022
|
| eccDNA (MYCN, CDK4, MDM2) |
Neuroblastoma |
Seismic amplification model |
Rosswog et al., 2021
|
| eccDNA (entire genome) |
Immune system |
Trigger immune response |
Wang et al., 2021
|
| TTNcircle
|
Musculoskeletal system |
Function of transcription |
Møller et al., 2018
|
| MI-related eccDNA (MIRECD) |
Myocardial infarction (MI) |
MI prognosis prediction and risk stratification |
Not yet published |
